Clinical Trials on Relapsed and/or Refractory Multiple Myeloma in Canada
Total 573 results
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Canadian Myeloma Research GroupGlaxoSmithKlineRecruitingRelapsed and/or Refractory Multiple MyelomaCanada
-
ORIC PharmaceuticalsRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Canada
-
ModernaTX, Inc.WithdrawnRelapsed or Refractory Multiple MyelomaUnited States, Canada
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaGermany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
-
PETHEMA FoundationGlaxoSmithKlineRecruitingRELAPSED AND/OR REFRACTORY MULTIPLE MYELOMASpain
-
TakedaTerminatedRelapsed and/or Refractory Multiple Myeloma (RRMM)United States, Canada
-
Hoffmann-La RocheRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada, Germany
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
GlaxoSmithKlineTerminatedRelapsed/Refractory Multiple MyelomaAustralia, Sweden, Canada
-
AmgenCompletedRelapsed or Refractory Multiple MyelomaUnited States, Belgium, Australia, Spain, Canada, Netherlands
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
-
Novartis PharmaceuticalsCompletedRelapsed or Refractory Multiple MyelomaUnited States, Turkey, Canada, Netherlands, Australia, Germany, France
-
Millennium Pharmaceuticals, Inc.CompletedRelapsed and/or Refractory Multiple MyelomaUnited States, France, Norway, Spain, Israel, United Kingdom, Italy, Australia, Germany, Greece, Canada, Czechia, Turkey, Russian Federation, Denmark, Sweden, Belgium, Netherlands
-
Bristol-Myers SquibbRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
-
CelgeneRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Ontario Clinical Oncology Group (OCOG)PfizerNot yet recruitingRefractory Multiple MyelomaCanada
-
PETHEMA FoundationCompletedRelapsed and Refractory Multiple MyelomaSpain
-
AmgenTerminatedRelapsed/Refractory Multiple MyelomaUnited States, Australia, Japan, Germany, Netherlands, Canada
-
University Health Network, TorontoMultiple Myeloma Research ConsortiumTerminatedMultiple Myeloma | Relapsed/RefractoryCanada
-
BeiGeneRecruitingRelapsed/Refractory Multiple MyelomaUnited States, China, Australia, Korea, Republic of, Canada, United Kingdom, Israel, Singapore, New Zealand, Brazil
-
Cleave Biosciences, Inc.TerminatedLymphoid Hematological Malignancies | Relapsed and Refractory Multiple MyelomaCanada, United States
-
University Health Network, TorontoAbbVie; CelgeneTerminatedAcute Myeloid Leukemia | Relapsed Cancer | Refractory Cancer | IDH2 Gene MutationCanada
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaCanada
-
AbbVieGenentech, Inc.CompletedRelapsed/Refractory Multiple MyelomaUnited States, Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
-
Regeneron PharmaceuticalsRecruitingRelapsed Refractory Multiple Myeloma (RRMM)Canada, United States, Korea, Republic of, Israel, Taiwan, Spain, Australia, Brazil, France, United Kingdom, Poland, Singapore, Netherlands, Italy
-
Ciusss de L'Est de l'Île de MontréalUnknownRelapsed Multiple Myeloma | Relapsed Non Hodgkin Lymphoma | Hematologic Cancer | Relapsed Adult AML | Relapse Leukemia | Relapsed Adult ALL | Relapsed CLL | Relapsed Hodgkin's Lymphoma | Relapsed Myelodysplastic SyndromesCanada
-
University of ChicagoNational Cancer Institute (NCI)Active, not recruitingStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple MyelomaUnited States, Canada
-
University Health Network, TorontoTakara Bio Inc.RecruitingRelapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell LymphomaCanada
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRecruitingMyeloma | Myeloma MultipleCanada
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada
-
University Health Network, TorontoActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Relapsed Cancer | Refractory CancerCanada
-
Washington University School of MedicineBristol-Myers Squibb; CelgeneActive, not recruitingMultiple Myeloma in RelapseUnited States, Canada
-
Canadian Myeloma Research GroupCompletedMultiple Myeloma in RelapseCanada
-
Arog Pharmaceuticals, Inc.RecruitingRelapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States, Germany, Spain, Italy, France, Canada
-
AEterna ZentarisCompletedMultiple Myeloma and Plasma Cell NeoplasmCanada
-
AmgenCompletedRelapsed Multiple MyelomaUnited States, Canada
-
British Columbia Cancer AgencyCanadian Urologic Oncology Group; German Testicular Cancer Study Group; NCIC...CompletedRelapsed or Cisplatin-Refractory Germ Cell CancerCanada
-
PETHEMA FoundationRecruitingMultiple Myeloma in RelapseSpain
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States, Canada
-
AHS Cancer Control AlbertaAbbott; Tom Baker Cancer CentreCompleted
-
Ottawa Hospital Research InstituteRecruiting
-
K36 Therapeutics, Inc.RecruitingMultiple Myeloma | Myeloma | Myeloma MultipleUnited States, France, Spain, Canada
-
Regeneron PharmaceuticalsRecruiting
-
AmgenCompletedRelapsed Multiple MyelomaUnited States, Canada, United Kingdom, France, Belgium, Austria, Spain, Israel, Italy, Bulgaria, Czechia, Germany, Greece, Hungary, Netherlands, Poland, Romania, Russian Federation, Serbia, Sweden
-
Allogene TherapeuticsRecruitingRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaUnited States, Spain, Canada, Australia, Italy
-
Karyopharm Therapeutics IncActive, not recruitingAcute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDSUnited States, France, Canada, Spain, China